Globe Newswire11.24.20
Conformis Inc. announced that 90 percent of the patients studied in peer-reviewed clinical research published online in The Journal of Bone and Joint Surgery Reviews were satisfied, or very satisfied, 18–28 months post-surgery. In addition, 88 percent of patients reported that their knees felt natural either some or all of the time.
The clinical study, conducted by U.S. orthopedic surgeons Vivekanand Neginhal and William Kurtz, and researcher Lennart Schroeder, was designed to test the hypothesis that the Conformis PS implant would drive high overall patient-reported outcomes because of its patient-specific design.
“This peer-reviewed clinical research is the latest in more than 30 studies published in medical journals that supports the strong performance of our patient-specific implants, which are designed to fit each patient’s unique anatomy,” said Mark Augusti, president and CEO. “While market research generally indicates that knee replacement with traditional knee implants fails to satisfy 20–30 percent of patients, we are pleased to once again see that our technology is a major contributor to much higher patient satisfaction, an end to chronic pain, and restoration of mobility.”
In addition to patient satisfaction rates, patient-reported outcomes were assessed utilizing the Knee injury and Osteoarthritis Outcome Score Joint Replacement (KOOS JR). KOOS JR interval scores range from 0 (total knee disability) to 100 (perfect knee health), and the average score for the patients studied was 90.
The researchers also found that the average preoperative baseline pain rating of 6.5 (range of three to 10) for the patients studied decreased by 5.2 on the numeric pain rating scale to an average of 1.3 (range of 0 to 8), which reflects a dramatic reduction in pain.
The final measure assessed was implant survivorship, which was found to be 100 percent at an average of 23 months post-op for the 100 knees included in the study.
The clinical study, conducted by U.S. orthopedic surgeons Vivekanand Neginhal and William Kurtz, and researcher Lennart Schroeder, was designed to test the hypothesis that the Conformis PS implant would drive high overall patient-reported outcomes because of its patient-specific design.
“This peer-reviewed clinical research is the latest in more than 30 studies published in medical journals that supports the strong performance of our patient-specific implants, which are designed to fit each patient’s unique anatomy,” said Mark Augusti, president and CEO. “While market research generally indicates that knee replacement with traditional knee implants fails to satisfy 20–30 percent of patients, we are pleased to once again see that our technology is a major contributor to much higher patient satisfaction, an end to chronic pain, and restoration of mobility.”
In addition to patient satisfaction rates, patient-reported outcomes were assessed utilizing the Knee injury and Osteoarthritis Outcome Score Joint Replacement (KOOS JR). KOOS JR interval scores range from 0 (total knee disability) to 100 (perfect knee health), and the average score for the patients studied was 90.
The researchers also found that the average preoperative baseline pain rating of 6.5 (range of three to 10) for the patients studied decreased by 5.2 on the numeric pain rating scale to an average of 1.3 (range of 0 to 8), which reflects a dramatic reduction in pain.
The final measure assessed was implant survivorship, which was found to be 100 percent at an average of 23 months post-op for the 100 knees included in the study.